Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

NCT02681302 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

46

Enrollment

OTHER

Sponsor class

Stopped Lack of Accrual

Conditions

Multiple Myeloma
Lymphoma

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Hackensack Meridian Health